Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641034 | 0.79 | S1PR5 (0.35) | S1PR5S1PR1CCR1 | |
| SCHEMBL14467573 | 0.79 | MAP3K14 (0.34) | MAP3K14IDO1TDO2 | |
| SCHEMBL13644052 | 0.78 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL13644057 | 0.78 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL12198930 | 0.74 | MAP3K14 (0.35) | MAP3K14IDO1TDO2CCR1 | |
| SCHEMBL12084406 | 0.73 | EBP (0.44) | MAP3K14 | |
| SCHEMBL13640989 | 0.72 | SIGMAR1 (0.51) | TSHR | |
| SCHEMBL13640814 | 0.72 | SIGMAR1 (0.51) | TSHR | |
| SCHEMBL13640839 | 0.72 | MAP3K14 (0.38) | MAP3K14IDO1TDO2NPY5RMAPT | |
| SCHEMBL13640944 | 0.71 | MAP3K14 (0.34) | MAP3K14IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | MAP3K14 1920/4885IDO1 1589/4885TDO2 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.